Weight-loss jabs could become the 'new statin' for heart treatment after US ... trends now
View
comments
Blockbuster weight-loss jab Wegovy could become 'the new statin' after regulators in the US approved it as a treatment for heart disease.
It follows the results of a major trial which found the drug, known as semaglutide, could slash the risk of a heart attack or stroke in people with obesity by around 20 per cent.
Around 50,000 people in the UK who are obese or have at least one other weight-related problem – which includes heart issues – are already eligible to get Wegovy on the NHS and will be getting those benefits.
But thousands more with heart disease who may be overweight but not obese could potentially get access to it in future after the company behind the drug, Novo Nordisk, applied to UK regulator the Medicines and Healthcare Products Regulatory Agency (MHRA) for a similar update.
Obesity expert Prof Naveed Sattar, at the University of Glasgow, told The Mail on Sunday that 'cardiologists are now starting to take serious note' of semaglutide as a treatment
